ReviewCancers2020
Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.
PATHOS Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Sarcopenia among treated cancer patients before and after neoadjuvant chemotherapy: a systematic review and meta-analysis of high-quality studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Efferent limb stimulation prior to loop ileostomy closure: a systematic review and meta-analysis.Techniques in coloproctology · 2023Pooled it
- Repurposing Antipsychotics in Cancer Therapy: Modulation of Autophagy Mechanisms.Clinical drug investigation · 2026Review
- Complete pathologic response surrogacy for survival and its predictors in locally advanced rectal cancer: a retrospective cohort study.International journal of colorectal disease · 2026Article
- Transformative Applications and Innovations in Next-Generation Sequencing Data Analysis.Journal of applied genetics · 2026Review
- Unique Considerations in Caring for Rural Patients with Rectal Cancer: A Scoping Review of the Literature from the USA and Canada.Journal of clinical medicine · 2025Review
- Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes.Journal of clinical medicine · 2025Review
- Therapeutic Management of Locally Advanced Rectal Cancer: Existing and Prospective Approaches.Journal of clinical medicine · 2025Review
- Surgery versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced gastrointestinal tract cancers.Frontiers in oncology · 2025Article
- Longitudinal Risk Analysis of Second Primary Cancer after Curative Treatment in Patients with Rectal Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.Cancers · 2024Review
- A nomogram based on MRI radiomics features of mesorectal fat for diagnosing T2- and T3-stage rectal cancer.Abdominal radiology (New York) · 2024Article
- Article
- YAP Promotes Chemoresistance to 5-FU in Colorectal Cancer Through mTOR/GLUT3 Axis.Journal of Cancer · 2024Article
- A Rare Case of Submandibular Gland Squamous Cell Carcinoma: Diagnostic Challenges and Surgical Management.Cureus · 2024Article
- Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways.Medical oncology (Northwood, London, England) · 2023Review
- Fully automated volumetric modulated arc therapy planning for locally advanced rectal cancer: feasibility and efficiency.Radiation oncology (London, England) · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Most clinical practice guidelines recommend a selective approach for rectal cancer after clinical staging. In low-risk patients, upfront surgery may be an appropriate option. However, in patients with MRI-defined high-risk features such as extramural vascular invasion, multiple nodal involvement or T4 and/or tumors close to or invading the mesorectal fascia, a more intensive preoperative approach is recommended, which may include neoadjuvant or preoperative chemotherapy. The potential benefits include better compliance than postoperative chemotherapy, a higher pathological complete remission rate, which facilitates a non-surgical approach, and earlier treatment of micrometastatic disease with improved disease-free survival compared to standard preoperative chemoradiation or short-course radiation. Two recently reported phase III randomized trials, RAPIDO and PRODIGE 23, show that adding neoadjuvant chemotherapy to either standard short-course radiation or standard long-course chemoradiation in locally advanced rectal cancer patients reduces the risk of metastasis and significantly prolongs disease-related treatment failure and disease-free survival. This review discusses these potentially practice-changing trials and how they may affect our current understanding of treating locally advanced rectal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.